# Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors
**Date:** 2026-03-27 02:05:00
**Company:** Novartis AG
**Ticker:** NVS
**Source URL:** https://www.globenewswire.com/news-release/2026/03/27/3263556/0/en/Excellergy-to-be-acquired-by-Novartis-for-up-to-USD-2-billion-to-advance-potentially-first-in-class-trifunctional-effector-cell-response-inhibitors.html
---
[Accessibility: Skip TopNav](https://www.globenewswire.com/news-release/2026/03/27/3263556/0/en/Excellergy-to-be-acquired-by-Novartis-for-up-to-USD-2-billion-to-advance-potentially-first-in-class-trifunctional-effector-cell-response-inhibitors.html#maincontainer)
[](https://www.globenewswire.com/)
- [Newsroom](https://www.globenewswire.com/newsroom)
- [Services](https://www.globenewswire.com/services)
- [Contact Us](https://insight.notified.c...
# Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors
**Date:** 2026-03-27 02:05:00
**Company:** Novartis AG
**Ticker:** NVS
**Source URL:** https://www.globenewswire.com/news-release/2026/03/27/3263556/0/en/Excellergy-to-be-acquired-by-Novartis-for-up-to-USD-2-billion-to-advance-potentially-first-in-class-trifunctional-effector-cell-response-inhibitors.html
---
[Accessibility: Skip TopNav](https://www.globenewswire.com/news-release/2026/03/27/3263556/0/en/Excellergy-to-be-acquired-by-Novartis-for-up-to-USD-2-billion-to-advance-potentially-first-in-class-trifunctional-effector-cell-response-inhibitors.html#maincontainer)
[](https://www.globenewswire.com/)
- [Newsroom](https://www.globenewswire.com/newsroom)
- [Services](https://www.globenewswire.com/services)
- [Contact Us](https://insight.notified.com/globenewswire-contact-us?utm_medium=Website&utm_source=Contact%20Us&utm_campaign=Contact%20Us%20ENG)
- [About Us](https://www.globenewswire.com/about)
- English
[Sign In](https://www.globenewswire.com/home/signin) [Register](https://portal.notified.com/en/registration)
# 
# Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors
March 27, 2026 02:05 ET\| Source:
[Excellergy, Inc.](https://www.globenewswire.com/en/search/organization/Excellergy%CE%B4%2520Inc%C2%A7)FollowExcellergy, Inc.
* * *
Share
- * * *
_– Acquisition brings together Excellergy's differentiated trifunctional allergic effector cell response inhibitors (ECRIs) and the development expertise of Novartis, with a total potential transaction value of up to $2 billion –_
_– Exl-111 is a potentially first-in-class allergic trifunctional ECRI targeting the IgE axis and is currently in Phase 1 development –_
PALO ALTO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- [Excellergy](https://www.globenewswire.com/Tracker?data=e19-1E_yemNXnYty-tDBi-TiXjoJndbqaRqKgvkd2p40XovpSqZYsXRy4uBYwW6TFEQlbXW13YBEpoybUTp5UQaHTf1vPNcywtKdAVuHcGqPdSpLuJBPo52P5L36smeCfzTA7NtKPSB9H5ZXbDwrJTcWEC1204zxGoMo20u3kFJbXrQl-HII1w4MAHp0LzAEAXTulv9NOal9AE5CadfPBVLRhIj9Md-k1IEbH4R28R_-PYrgQsv_ftsqYVVJe4lqBeXJzRnNJOW14QQwM7fxOT2Rh9n-_0Cvuy-YgS3sVMvW-Xde3cef6i-6fuh179nsxbdnmLQ1fRDy6CB9_eAQGvZwjRzkebLvHsRU4ikkIqcnF2HnV8ttLaH2OrUYw7Rm "Excellergy"), a biotechnology company developing a novel class of allergy therapeutics, today announced it will be acquired by Novartis in a transaction with a total potential value of up to $2 billion in upfront and milestone payments. The acquisition brings together Excellergy's novel trifunctional ECRIs with the development expertise of Novartis.
Exl-111 is a trifunctional ECRI designed to disarm allergic effector cells at the source of activation by targeting the IgE axis. Exl-111 is currently being evaluated in the Phase 1 DISARM trial, a randomized, double-blind, placebo-controlled, single and multiple ascending dose trial, with the first subjects dosed in early February 2026.
"This acquisition validates the transformative potential of our ECRIs and the hard work of the entire Excellergy team. Novartis brings world-class global development capabilities and a proven track record of bringing novel medicines to patients. Together, we will be ideally positioned to realize the full potential of Exl-111 and the broader ECRI pipeline for the millions of patients living with severe, debilitating allergic diseases", said **Todd Zavodnick, Chief Executive Officer of Excellergy**.
“Excellergy adds a differentiated next-generation anti-IgE program that builds on biology Novartis knows well, supported by preclinical evidence and early clinical pharmacokinetic data,” said **Fiona Marshall, President of Biomedical Research at Novartis**. “Exl-111 is designed to go beyond conventional anti-IgE therapy, with the potential to deliver faster and deeper suppression of IgE signaling as well as improved symptom control. This proposed acquisition strengthens our allergy portfolio and reflects our strategy of advancing innovative bold science to bring meaningful additional benefits to patients.”
Excellergy was seeded in 2021 by Red Tree Venture Capital and is backed by Samsara BioCapital, Red Tree Venture Capital, and Decheng Capital.
The transaction is subject to customary closing conditions.
**Advisors**
J.P. Morgan Securities LLC served as exclusive financial advisor, and Wilson Sonsini Goodrich & Rosati served as legal counsel to Excellergy on the transaction.
[**About Excellergy**](https://www.globenewswire.com/Tracker?data=LcyAKmzl6P0WdNfIUJMwgaforFgho-GdIz5N-E-dNFIov6I3VuWZcfLkZhBwpraLenf6RkPhPskWYEmPcapbMvASceVYX_kJ74rTFh2Tq_-PxLDXO_t_IXEDL_v3qpKeI4gG3f0AAPUh15zK0khhB_KEko6qvNM7MxPa4itD-pCCi4htQE1SboD6G81JAUcDi9mG8DlksIg_-MO2GihG88oOwaIxh-lnHPXKuUoTyIYnzaR8aiO_Oc3-SeZpvMDiQLP_jFIxiRDXytWEUf_K8mi2S9imQSd368E6NZiltswuJk2JlfR4O-PZjPMz4rcb7CesMjDZ9qvMDL9dt963pXbXwsE2ang4TImRWjqdfmUC_HWpIR9R0x0L8YDEiOb9I2OVAQ6dti96y4zjzm_JwQ== "")
Excellergy is a biotechnology company developing a potentially **first-in-class portfolio of Effector Cell Response Inhibitors (ECRIs)** for the treatment of severe IgE-mediated allergic diseases. By building on clinically validated IgE biology while introducing a new level of allergic disease control, Excellergy is advancing beyond traditional anti-IgE approaches to directly target the source of allergic signaling—IgE bound to the effector cell. The Company is headquartered in Palo Alto, California, and is backed by **Red Tree Venture Capital,** **Samsara BioCapital and Decheng Capital.** To learn more, please visit [www.excellergy.com](https://www.globenewswire.com/Tracker?data=SQrvg4yPVqf1Oag3XEq0XkviKO7g5L6vjEkuX48hvr21TWsylLfXfOqQ6dIsHROnAUxToxlHa44LCeAgVucCs2iAjRBBAmhSKDVwN9RIclMyw3ApeD-SODU800SHeb-8byV_ZKDu6WCmV9EUMGdSLzyRr86-IlzvRK7KKd2_spoXKsTOf9qLYoJW-p4rG-wnQzFYda40E18czuUildi3h2vG2UNyd8RS1d9b056RF82m6kg24WknKhrOZzv5h2fvipZFFp32nqMiFW2ZpLMF47gfGvvXozIvNgR4O7S-MUZfg5iAWg9VqCV1XDuz1uW-uFmqYBDd4s25r5vK9D9PGcE-NNOQs4z0dCd22G4OT_3VrH9DJ44dCzqjK3Z6OeYD "www.excellergy.com").
**Excellergy Media Contact:**
Jenn Gordon
dna Communications
[jgordon@dnacommunications.com](https://www.globenewswire.com/Tracker?data=bhZimBsXGUUmumK39-dKTiqwLAcJu_vHHFn1fkNEKGdJG02OIqvNumBGgpwhX7L85FmVxe0ySverQA7qqdFEv8ofmatv3570dS8rUYPPOKz6b35cyHnhs6_mHksJmiEI "jgordon@dnacommunications.com")
**Excellergy Investor Contact:**
Laurence Watts
New Street Investor Relations
[laurence@newstreetir.com](https://www.globenewswire.com/Tracker?data=ghkTDpVWjXHv5Eq6OLncuKuv9wsY9JVz0f-ST5B5eLMnYIazt0wqz7xPrF6r0U3W1FCAflid56os1X9XcerXFiZst53gEHTgT6C02tqC0-MZnEe4PSDdj-aQL98v87ZE "laurence@newstreetir.com")
* * *
## Tags
[excellergy](https://www.globenewswire.com/en/search/tag/excellergy "excellergy")[allergic](https://www.globenewswire.com/en/search/tag/allergic "allergic")[allergic disease](https://www.globenewswire.com/en/search/tag/allergic%2520disease "allergic disease")[allergic disease control](https://www.globenewswire.com/en/search/tag/allergic%2520disease%2520control "allergic disease control")[allergy](https://www.globenewswire.com/en/search/tag/allergy "allergy")[DISARM trial](https://www.globenewswire.com/en/search/tag/disarm%2520trial "DISARM trial")[ECRI](https://www.globenewswire.com/en/search/tag/ecri "ECRI")[ECRIs](https://www.globenewswire.com/en/search/tag/ecris "ECRIs")[response inhibitors](https://www.globenewswire.com/en/search/tag/response%2520inhibitors "response inhibitors")[Effector Cell](https://www.globenewswire.com/en/search/tag/effector%2520cell "Effector Cell")
GlobeNewswire
Release SummaryExcellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors
Press Release Actions
- [Print](https://www.globenewswire.com/news-release/2026/03/27/3263556/0/en/Excellergy-to-be-acquired-by-Novartis-for-up-to-USD-2-billion-to-advance-potentially-first-in-class-trifunctional-effector-cell-response-inhibitors.html?print=1)
- [Download PDF](https://www.globenewswire.com/news-release/2026/03/27/3263556/0/en/Excellergy-to-be-acquired-by-Novartis-for-up-to-USD-2-billion-to-advance-potentially-first-in-class-trifunctional-effector-cell-response-inhibitors.html?pdf=1)
- [Subscribe via RSS](https://www.globenewswire.com/rssfeed/organization/kNt-X3tTAQNCRNA54q8Lkw==)
- [Subscribe via ATOM](https://www.globenewswire.com/atomfeed/organization/kNt-X3tTAQNCRNA54q8Lkw==)
- [Javascript](https://www.globenewswire.com/JSWidget/organization/iFPShl9nMY_lhnK-BImMjg%3d%3d)
## Recommended Reading
- February 27, 2026 15:45 ET\|Source: [Excellergy, Inc.](https://www.globenewswire.com/en/search/organization/Excellergy%CE%B4%2520Inc%C2%A7)
[Excellergy Presents New Data at 2026 AAAAI Annual Meeting Demonstrating Rapid and Sustained Allergic Effector Cell Control and Announces First Subjects Dosed in Phase 1 DISARM Trial](https://www.globenewswire.com/news-release/2026/02/27/3246778/0/en/Excellergy-Presents-New-Data-at-2026-AAAAI-Annual-Meeting-Demonstrating-Rapid-and-Sustained-Allergic-Effector-Cell-Control-and-Announces-First-Subjects-Dosed-in-Phase-1-DISARM-Tria.html)
Excellergy Presents New Data at 2026 AAAAI Annual Meeting Demonstrating Rapid and Sustained Allergic Effector Cell Control
[Read More](https://www.globenewswire.com/news-release/2026/02/27/3246778/0/en/Excellergy-Presents-New-Data-at-2026-AAAAI-Annual-Meeting-Demonstrating-Rapid-and-Sustained-Allergic-Effector-Cell-Control-and-Announces-First-Subjects-Dosed-in-Phase-1-DISARM-Tria.html)
[View More News](https://www.globenewswire.com/en/newsroom)
## Explore
Previous
[](https://www.globenewswire.com/news-release/2026/03/27/3263545/0/en/MidPoint-Capital-Partners-LLC-Announces-500-Million-Private-Real-Estate-Lending-Fund.html)
March 27, 2026 01:40 ET
[MidPoint Capital Partners, LLC Announces $500 Mill...](https://www.globenewswire.com/news-release/2026/03/27/3263545/0/en/MidPoint-Capital-Partners-LLC-Announces-500-Million-Private-Real-Estate-Lending-Fund.html "MidPoint Capital...")
[](https://www.globenewswire.com/news-release/2026/03/27/3263544/0/en/iYUREK-Launches-Stress-Meter-Pro-for-Smarter-Trading.html)
March 27, 2026 01:36 ET
[iYUREK Launches Stress Meter Pro for Smarter Tradi...](https://www.globenewswire.com/news-release/2026/03/27/3263544/0/en/iYUREK-Launches-Stress-Meter-Pro-for-Smarter-Trading.html "iYUREK Launches...")
[](https://www.globenewswire.com/news-release/2026/03/27/3263543/0/en/DEEP-Robotics-Lynx-M20-Wheeled-Legged-Robot-Wins-iF-Design-Award.html)
March 27, 2026 01:34 ET
[DEEP Robotics Lynx M20 Wheeled-Legged Robot Wins i...](https://www.globenewswire.com/news-release/2026/03/27/3263543/0/en/DEEP-Robotics-Lynx-M20-Wheeled-Legged-Robot-Wins-iF-Design-Award.html "DEEP Robotics Lynx M...")
[](https://www.globenewswire.com/news-release/2026/03/27/3263547/0/en/2-5-Billion-Syndication-Lending-Powers-Dubai-s-Solar-City-Vision-in-Desert.html)
March 27, 2026 01:51 ET
[$2.5 Billion Syndication Lending Powers Dubai's So...](https://www.globenewswire.com/news-release/2026/03/27/3263547/0/en/2-5-Billion-Syndication-Lending-Powers-Dubai-s-Solar-City-Vision-in-Desert.html "$2.5 Billion...")
[](https://www.globenewswire.com/news-release/2026/03/27/3263546/0/en/Apparel-Group-x-Steve-Madden-Lead-a-GCC-Wide-CSR-Initiative-with-Leading-NGOs-to-Support-Children-of-Determination.html)
March 27, 2026 01:48 ET
[Apparel Group x Steve Madden Lead a GCC-Wide CSR I...](https://www.globenewswire.com/news-release/2026/03/27/3263546/0/en/Apparel-Group-x-Steve-Madden-Lead-a-GCC-Wide-CSR-Initiative-with-Leading-NGOs-to-Support-Children-of-Determination.html "Apparel Group x...")
[](https://www.globenewswire.com/news-release/2026/03/27/3263545/0/en/MidPoint-Capital-Partners-LLC-Announces-500-Million-Private-Real-Estate-Lending-Fund.html)
March 27, 2026 01:40 ET
[MidPoint Capital Partners, LLC Announces $500 Mill...](https://www.globenewswire.com/news-release/2026/03/27/3263545/0/en/MidPoint-Capital-Partners-LLC-Announces-500-Million-Private-Real-Estate-Lending-Fund.html "MidPoint Capital...")
[](https://www.globenewswire.com/news-release/2026/03/27/3263544/0/en/iYUREK-Launches-Stress-Meter-Pro-for-Smarter-Trading.html)
March 27, 2026 01:36 ET
[iYUREK Launches Stress Meter Pro for Smarter Tradi...](https://www.globenewswire.com/news-release/2026/03/27/3263544/0/en/iYUREK-Launches-Stress-Meter-Pro-for-Smarter-Trading.html "iYUREK Launches...")
[](https://www.globenewswire.com/news-release/2026/03/27/3263543/0/en/DEEP-Robotics-Lynx-M20-Wheeled-Legged-Robot-Wins-iF-Design-Award.html)
March 27, 2026 01:34 ET
[DEEP Robotics Lynx M20 Wheeled-Legged Robot Wins i...](https://www.globenewswire.com/news-release/2026/03/27/3263543/0/en/DEEP-Robotics-Lynx-M20-Wheeled-Legged-Robot-Wins-iF-Design-Award.html "DEEP Robotics Lynx M...")
[](https://www.globenewswire.com/news-release/2026/03/27/3263547/0/en/2-5-Billion-Syndication-Lending-Powers-Dubai-s-Solar-City-Vision-in-Desert.html)
March 27, 2026 01:51 ET
[$2.5 Billion Syndication Lending Powers Dubai's So...](https://www.globenewswire.com/news-release/2026/03/27/3263547/0/en/2-5-Billion-Syndication-Lending-Powers-Dubai-s-Solar-City-Vision-in-Desert.html "$2.5 Billion...")
[](https://www.globenewswire.com/news-release/2026/03/27/3263546/0/en/Apparel-Group-x-Steve-Madden-Lead-a-GCC-Wide-CSR-Initiative-with-Leading-NGOs-to-Support-Children-of-Determination.html)
March 27, 2026 01:48 ET
[Apparel Group x Steve Madden Lead a GCC-Wide CSR I...](https://www.globenewswire.com/news-release/2026/03/27/3263546/0/en/Apparel-Group-x-Steve-Madden-Lead-a-GCC-Wide-CSR-Initiative-with-Leading-NGOs-to-Support-Children-of-Determination.html "Apparel Group x...")
[](https://www.globenewswire.com/news-release/2026/03/27/3263545/0/en/MidPoint-Capital-Partners-LLC-Announces-500-Million-Private-Real-Estate-Lending-Fund.html)
March 27, 2026 01:40 ET
[MidPoint Capital Partners, LLC Announces $500 Mill...](https://www.globenewswire.com/news-release/2026/03/27/3263545/0/en/MidPoint-Capital-Partners-LLC-Announces-500-Million-Private-Real-Estate-Lending-Fund.html "MidPoint Capital...")
[](https://www.globenewswire.com/news-release/2026/03/27/3263544/0/en/iYUREK-Launches-Stress-Meter-Pro-for-Smarter-Trading.html)
March 27, 2026 01:36 ET
[iYUREK Launches Stress Meter Pro for Smarter Tradi...](https://www.globenewswire.com/news-release/2026/03/27/3263544/0/en/iYUREK-Launches-Stress-Meter-Pro-for-Smarter-Trading.html "iYUREK Launches...")
[](https://www.globenewswire.com/news-release/2026/03/27/3263543/0/en/DEEP-Robotics-Lynx-M20-Wheeled-Legged-Robot-Wins-iF-Design-Award.html)
March 27, 2026 01:34 ET
[DEEP Robotics Lynx M20 Wheeled-Legged Robot Wins i...](https://www.globenewswire.com/news-release/2026/03/27/3263543/0/en/DEEP-Robotics-Lynx-M20-Wheeled-Legged-Robot-Wins-iF-Design-Award.html "DEEP Robotics Lynx M...")
Next
About Us
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases, financial disclosures and multimedia content to media, investors, and consumers worldwide.
Global News
- [English](https://www.globenewswire.com/newsroom)
- [Français](https://www.globenewswire.com/fr/newsroom)
- [Deutsch](https://www.globenewswire.com/de/newsroom)
Newswire Distribution Network & Management
- [Home](https://www.globenewswire.com/)
- [Newsroom](https://www.globenewswire.com/newsroom)
- [RSS Feeds](https://www.globenewswire.com/rss/list)
- [Notified](https://www.notified.com/)
- [Legal](https://www.notified.com/privacy)
- [About Us](https://www.globenewswire.com/about)
- [Contact Us](https://insight.notified.com/globenewswire-contact-us?utm_medium=Website&utm_source=Contact%20Us&utm_campaign=Contact%20Us%20ENG)
- [Resources](https://www.notified.com/resources)
© 2026 Digital Media Innovations, LLC. All rights reserved.
[GlobeNewswire Linkedin](https://www.linkedin.com/company/1006947 "GlobeNewswire Linkedin") [Notified Twitter](https://twitter.com/Notified "Notified Twitter")
;
[Français](https://www.globenewswire.com/fr/news-release/2026/03/27/3263556/0/en/Excellergy-to-be-acquired-by-Novartis-for-up-to-USD-2-billion-to-advance-potentially-first-in-class-trifunctional-effector-cell-response-inhibitors.html) [Deutsch](https://www.globenewswire.com/de/news-release/2026/03/27/3263556/0/en/Excellergy-to-be-acquired-by-Novartis-for-up-to-USD-2-billion-to-advance-potentially-first-in-class-trifunctional-effector-cell-response-inhibitors.html)